Publications
Detailed Information
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Park, In Ae | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2017-02-03T02:17:12Z | - |
dc.date.available | 2017-02-03T02:17:12Z | - |
dc.date.created | 2020-04-08 | - |
dc.date.created | 2020-04-08 | - |
dc.date.issued | 2011-03 | - |
dc.identifier.citation | Breast Cancer Research, Vol.13 No.2, p. R22 | - |
dc.identifier.issn | 1465-5411 | - |
dc.identifier.other | 95272 | - |
dc.identifier.uri | https://hdl.handle.net/10371/100405 | - |
dc.description | This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | ko_KR |
dc.description.abstract | Introduction: Triple negative breast cancer (TNBC) has a poorer survival, despite a higher response rate to neoadjuvant chemotherapy. The purpose of this study was to identify the predictive or prognostic value of Ki-67 among patients with TNBC treated with neoadjuvant chemotherapy, and the role of Ki-67 in further classification of TNBC. Methods: A total of 105 TNBC patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were included in the present study. Pathologic complete response (pCR) rate, relapse-free survival (RFS), and overall survival (OS) were compared according to the level of Ki-67. Results: pCR was observed in 13.3% of patients. TNBC with high Ki-67 expression (>= 10%) showed a higher pCR rate to neoadjuvant chemotherapy than TNBC with low Ki-67 expression. None of the low Ki-67 group achieved pCR (18.2% in the high Ki-67 group vs. 0.0% in the low Ki-67 group, P = 0.019). However, a high Ki-67 expression was significantly associated with poor RFS and OS in TNBC, despite a higher pCR rate (P = 0.005, P = 0.019, respectively). In multivariate analysis, high Ki-67 was an independent prognostic factor for RFS in TNBC (hazard ratio = 7.82, P = 0.002). The high Ki-67 group showed a similar pattern of recurrence with overall TNBC, whereas the low Ki-67 group demonstrated a relatively constant hazard rate for relapse. Conclusions: TNBC with high Ki-67 was associated with a more aggressive clinical feature despite a higher pCR rate. High proliferation index Ki-67 can be used for further classification of TNBC into two subtypes with different responses and prognosis. | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | - |
dc.title | Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1186/bcr2834 | - |
dc.citation.journaltitle | Breast Cancer Research | - |
dc.identifier.wosid | 000292694600011 | - |
dc.identifier.scopusid | 2-s2.0-84860390436 | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | Keam et al.; licensee BioMed Central Ltd. | - |
dc.date.updated | 2017-01-29T03:04:06Z | - |
dc.citation.number | 2 | - |
dc.citation.startpage | R22 | - |
dc.citation.volume | 13 | - |
dc.identifier.sci | 000292694600011 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Han, Wonshik | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Park, In Ae | - |
dc.contributor.affiliatedAuthor | Noh, Dong-Young | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY KI-67 | - |
dc.subject.keywordPlus | PREOPERATIVE CHEMOTHERAPY | - |
dc.subject.keywordPlus | NEOADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | PREDICTIVE MARKERS | - |
dc.subject.keywordPlus | GROWTH FRACTIONS | - |
dc.subject.keywordPlus | PRIMARY TUMOR | - |
dc.subject.keywordPlus | IN-SITU | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.